Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab

Nivolumab prolonged disease control in a patient with advanced squamous lung cancer that was refractory to multiple treatments. The rapid eradication of cancer after the administration of nivolumab caused hemoptysis and repeated infection. Six months after immunotherapy, mediastinal lymph node metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yinghua, Jiang, Qiuying, Xin, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754313/
https://www.ncbi.nlm.nih.gov/pubmed/29027754
http://dx.doi.org/10.1111/1759-7714.12522
_version_ 1783290387550437376
author Jin, Yinghua
Jiang, Qiuying
Xin, Tao
author_facet Jin, Yinghua
Jiang, Qiuying
Xin, Tao
author_sort Jin, Yinghua
collection PubMed
description Nivolumab prolonged disease control in a patient with advanced squamous lung cancer that was refractory to multiple treatments. The rapid eradication of cancer after the administration of nivolumab caused hemoptysis and repeated infection. Six months after immunotherapy, mediastinal lymph node metastasis developed and afatinib effectively relieved dysphonia associated with nerve paralysis.
format Online
Article
Text
id pubmed-5754313
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-57543132018-01-09 Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab Jin, Yinghua Jiang, Qiuying Xin, Tao Thorac Cancer Case Reports Nivolumab prolonged disease control in a patient with advanced squamous lung cancer that was refractory to multiple treatments. The rapid eradication of cancer after the administration of nivolumab caused hemoptysis and repeated infection. Six months after immunotherapy, mediastinal lymph node metastasis developed and afatinib effectively relieved dysphonia associated with nerve paralysis. John Wiley & Sons Australia, Ltd 2017-10-13 2018-01 /pmc/articles/PMC5754313/ /pubmed/29027754 http://dx.doi.org/10.1111/1759-7714.12522 Text en © 2017 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Jin, Yinghua
Jiang, Qiuying
Xin, Tao
Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab
title Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab
title_full Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab
title_fullStr Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab
title_full_unstemmed Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab
title_short Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab
title_sort afatinib treatment of a squamous lung cancer after tumor progression of nivolumab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754313/
https://www.ncbi.nlm.nih.gov/pubmed/29027754
http://dx.doi.org/10.1111/1759-7714.12522
work_keys_str_mv AT jinyinghua afatinibtreatmentofasquamouslungcanceraftertumorprogressionofnivolumab
AT jiangqiuying afatinibtreatmentofasquamouslungcanceraftertumorprogressionofnivolumab
AT xintao afatinibtreatmentofasquamouslungcanceraftertumorprogressionofnivolumab

Ejemplares similares